Research report · Public share

科伦药业

CN · 002422 · 2026-10-27 · Full research
Neutral
Investment opportunity现价39.84元已基本公允(三情景概率加权约39.9元、赔率对称、无静态安全边际),未来18个月的机会属事件验证型:先过10-29三季报扣非收窄门槛,再看sac-TMT中国1L双适应症(K2/K3)与美国首项BLA(K4)能否接力兑现上行期权;市值结构上科伦≈博泰与川宁股权市值之和(市场按折价持有通道定价,博泰市值锚含高预期与一次性损益),主业扣非下行与川宁周期构成先手风险。
How was this report? Leave anonymous feedback.
This report was generated automatically by Loyan AI. For research reference only — not investment advice.
Want a research assistant that never forgets and challenges its own views?
Sign in to add this research to your library, or register for free to get started.
Sign in / register free
科伦药业 · Full research — Loyan AI Research Partner